Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Toshihiko, Ohtomo"'
Autor:
Kenji Yorita, Akinobu Ohno, Takahiro Nishida, Kazuhiro Kondo, Toshihiko Ohtomo, Hiroaki Kataoka
Publikováno v:
BMC Research Notes, Vol 12, Iss 1, Pp 1-7 (2019)
Abstract Objective We previously reported the identification of monocarboxylate transporter 4 (MCT4) and glypican-3 (GPC3) as prognostic factors for hepatocellular carcinoma (HCC), which are now considered significant poor prognostic factors for the
Externí odkaz:
https://doaj.org/article/7ffba7fdb7ab4aa1ad8b1576abafdd23
Autor:
Melanie F. Pradier, Bernhard Reis, Lori Jukofsky, Francesca Milletti, Toshihiko Ohtomo, Fernando Perez-Cruz, Oscar Puig
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therap
Externí odkaz:
https://doaj.org/article/c84e3057b2a241b69d2832c6f9702481
Autor:
Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo, Ghassan K. Abou-Alfa
Publikováno v:
EJNMMI Research, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Background I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Se
Externí odkaz:
https://doaj.org/article/58e51e59a3e54e3985147d1bf44c110e
Autor:
Ghassan K. Abou-Alfa, Takehiko Kawanishi, Norihisa Ohishi, Mikiko Nakamura, Chao Xu, Ya-Chi Chen, Ruey-min Lee, Satofumi Iida, Toshihiko Ohtomo, Cheikh Diack
Publikováno v:
British Journal of Clinical Pharmacology. 84:944-951
Aims Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican-3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a63d9fac220809ff306179b3fa5845a1
https://doi.org/10.1111/bcp.13530
https://doi.org/10.1111/bcp.13530
Autor:
Norihisa Ohishi, Ghassan K. Abou-Alfa, Toshihiko Ohtomo, Neeta Pandit-Taskar, Serge K. Lyashchenko, Joseph A. O'Donoghue, Peter Smith-Jones, Volkan Beylergil, Steven M. Larson, Shutian Ruan, Jorge A. Carrasquillo
Publikováno v:
EJNMMI Research, Vol 8, Iss 1, Pp 1-11 (2018)
EJNMMI Research
EJNMMI Research
Background I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b60c65915e517fde9a75deb46d0df0a
http://link.springer.com/article/10.1186/s13550-018-0374-8
http://link.springer.com/article/10.1186/s13550-018-0374-8
Autor:
Francesca Milletti, Melanie F. Pradier, Lori Jukofsky, Oscar Puig, Toshihiko Ohtomo, Bernhard Reis, Fernando Perez-Cruz
Publikováno v:
BMC Cancer, 19
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
BMC Cancer
Background Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Biomar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4037610a2cf59a5be2210d2c0851bb43
https://hdl.handle.net/20.500.11850/338187
https://hdl.handle.net/20.500.11850/338187
Autor:
Reham Abdel-Wahab, Ahmed S Shalaby, Manal Hassan, Robert A. Wolff, Asif Rashid, Bharathi Vennapusa, James C. Yao, Hesham M. Amin, Sahin Lacin, Toshihiko Ohtomo, Ahmed Omar Kaseb, Janine Feng
Publikováno v:
Oncotarget
// Ahmed Omar Kaseb 1 , Manal Hassan 1 , Sahin Lacin 1, 3, * , Reham Abdel-Wahab 1, 4, * , Hesham M. Amin 2 , Ahmed Shalaby 1 , Robert A. Wolff 1 , James Yao 1 , Asif Rashid 2 , Bharathi Vennapusa 5 , Janine Feng 5 , Toshihiko Ohtomo 6 1 Department o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d424ced7acc0fb5ebfc579b1993f3baa
https://doi.org/10.18632/oncotarget.12066
https://doi.org/10.18632/oncotarget.12066
Autor:
Kenji Yorita, Kazuhiro Kondo, Jun Amano, Akinobu Ohno, Hiroaki Kataoka, Toshihiko Ohtomo, Tetsuji Yamaguchi, Yukihiro Haruyama, Sachiko Kitajima
Publikováno v:
International Journal of Cancer. 137:1643-1651
Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored cell surface glycoprotein overexpressed in hepatocellular carcinoma (HCC) cells and may serve as a potential molecular target for therapeutic intervention. This study evaluated the prognost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e935d216cf3a301caffb0fb48101ca09
https://doi.org/10.1002/ijc.29518
https://doi.org/10.1002/ijc.29518
Autor:
Mikiko, Nakamura, Chao, Xu, Cheikh, Diack, Norihisa, Ohishi, Ruey-Min, Lee, Satofumi, Iida, Takehiko, Kawanishi, Toshihiko, Ohtomo, Ghassan K, Abou-Alfa, Ya-Chi, Chen
Publikováno v:
British journal of clinical pharmacology. 84(5)
AIMS: Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican‐3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::843124b866db4624a417477c60696099
https://pubmed.ncbi.nlm.nih.gov/29381229
https://pubmed.ncbi.nlm.nih.gov/29381229
Autor:
Takayoshi Tanaka, Toshihiko Ohtomo, Ghassan K. Abou-Alfa, Volkan Beylergil, Zhong Zhe Lin, Ya Chi Chen, Jennifer Ma, Joseph A. O'Donoghue, Catherine Frenette, Tamara Agajanov, Frederic Boisserie, Ray Lee, Ann-Lii Cheng, Norihisa Ohishi, Bert H. O'Neil, Lawrence H. Schwartz, Yu-Yun Shao, Steven M. Larson, Jorge A. Carrasquilo, Shutian Ruan, Serge K. Lyashchenko, Bolorsukh Gansukh, Hideo Morikawa, Chia Jui Yen, Chih-Hung Hsu, Peter Justin Wan, Yuko Maki, Laura Di Laurenzio, Neeta Pandit-Taskar, Peter Smith-Jones
Codrituzumab, a humanized antibody against glypican-3, is highly expressed in HCC. A phase I study evaluated the combination with sorafenib in HCC. In a 3 + 3 design, codrituzumab was given intravenously in various doses with sorafenib 400 mg twice d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60257f3261ce85fe5726517b90bc4cd3
https://europepmc.org/articles/PMC5548107/
https://europepmc.org/articles/PMC5548107/